Supreet Agarwal

Supreet Agarwal has extensive work experience in the field of scientific research and pharmaceuticals. They have held various roles throughout their career, starting with a Ph.D. in Clinical Pharmaceutical Sciences from the University of Iowa, where they focused on the pharmacogenomics of glioma response to therapy. During this time, Supreet Agarwal discovered alterations of protein tyrosine phosphatase receptor type K (PTPRK) associated with worse survival and response to treatment.

After completing their Ph.D., Supreet Agarwal worked as a Postdoctoral Fellow at the National Cancer Institute (NCI), where they characterized the plasticity of luminal prostate cancer progenitor cells and established well-characterized prostate cancer models. They developed an ex vivo organoid system and identified luminal progenitor lineages with intrinsic resistance to therapy.

Following their role at NCI, Supreet Agarwal joined Astrix Technology Group as a Scientist, where they investigated the role of STAT1/interferon signaling in prostate cancer growth and response to therapeutics. They characterized the role of STAT1-driven interferon signaling in mouse models and patient-derived organoid models of prostate cancer.

Supreet Agarwal then returned to the National Cancer Institute as a Research Fellow (Scientist), where they explored mechanisms of therapy resistance in advanced metastatic prostate cancer. They developed a wide range of molecular biology techniques and biochemical assays for human and mouse prostate cancer organoids and identified autonomous chronic activation of interferon signaling as a mechanism of intrinsic therapy resistance.

Most recently, Supreet Agarwal joined Loxo@Lilly as a Senior Scientific Lead, where they are currently working. The specific responsibilities and accomplishments in this role are not provided in the given information.

In addition to their research experience, Supreet Agarwal has also worked as a Data Science Fellow, organizing and evaluating datasets and applying statistical analyses to evaluate factors predicting systolic blood pressure.

Overall, Supreet Agarwal has a strong background in scientific research, particularly in the field of cancer biology and pharmacogenomics. They have published peer-reviewed articles, obtained grant funding, and presented their research at national and international meetings.

Supreet Agarwal completed a PhD in Clinical Pharmaceutical Sciences/Pharmacogenomics at the University of Iowa from 2008 to 2012. Prior to that, they obtained a BS in Pharmacy from the Indian Institute of Technology (Banaras Hindu University), Varanasi from 2003 to 2007.